

Electromed, Inc.  
Form 10-Q  
May 13, 2011  
Table of Contents

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 10-Q**

---

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2011

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from \_\_\_\_\_ to \_\_\_\_\_.

Commission File No.: 001-34839

---

**Electromed, Inc.**

(Exact name of registrant as specified in its charter)

**Minnesota**  
(State or other jurisdiction of  
incorporation or organization)

**41-1732920**  
(IRS Employer  
Identification No.)

**500 Sixth Avenue NW, New Prague, MN**  
(Address of principal executive offices)

**(952) 758-9299**  
(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

Edgar Filing: Electromed, Inc. - Form 10-Q

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  
Yes o No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

- Large accelerated filer
- Accelerated filer
- Non-accelerated filer
- Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  
Yes o No x

There were 8,099,885 shares of Electromed, Inc. common stock, par value \$0.01, outstanding as of the close of business on May 12, 2011.

**Electromed, Inc.**  
**Index to Quarterly Report on Form 10-Q**

	Page No.
<u>PART I. FINANCIAL INFORMATION</u>	
<u>Item 1 Condensed Consolidated Financial Statements</u>	3
<u>Condensed Consolidated Balance Sheets as of March 31, 2011 (unaudited) and June 30, 2010</u>	3
<u>Condensed Consolidated Statements of Income (unaudited) for the three-month and nine-month periods ended March 31, 2011 and 2010</u>	4
<u>Condensed Consolidated Statements of Cash Flows (unaudited) for the nine-month periods ended March 31, 2011 and 2010</u>	5
<u>Notes to Interim Unaudited Condensed Consolidated Financial Statements</u>	6
<u>Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	10
<u>Item 3 Quantitative and Qualitative Disclosures About Market Risk</u>	18
<u>Item 4 Controls and Procedures</u>	18
<u>PART II. OTHER INFORMATION</u>	
<u>Item 1 Legal Proceedings</u>	18
<u>Item 1A Risk Factors</u>	19
<u>Item 2 Unregistered Sales of Equity Securities and Use of Proceeds</u>	19
<u>Item 3 Defaults Upon Senior Securities</u>	19
<u>Item 4 (Removed and Reserved)</u>	20
<u>Item 5 Other Information</u>	20
<u>Item 6 Exhibits</u>	20
<u>Signatures</u>	21
<u>Exhibit Index</u>	22



Table of Contents**PART I FINANCIAL INFORMATION****Item 1. Condensed Consolidated Financial Statements****Electromed, Inc. and Subsidiary  
Condensed Consolidated Balance Sheets**

	<b>March 31 2011 (Unaudited)</b>	<b>June 30 2010</b>
<b>Assets</b>		
Current Assets		
Cash and cash equivalents	\$ 3,952,032	\$ 610,727
Accounts receivable (net of allowances for doubtful accounts of \$45,000)	9,232,544	6,577,002
Inventories	1,664,965	1,470,775
Prepaid expenses and other current assets	324,519	269,193
Deferred income taxes	514,000	514,000
<b>Total current assets</b>	<b>15,688,060</b>	<b>9,441,697</b>
Property and equipment, net	2,770,695	2,688,941
Finite-life intangible assets, net	1,255,235	1,055,776
Deferred common stock offering costs		828,034
Other assets	191,895	128,789
<b>Total assets</b>	<b>\$ 19,905,885</b>	<b>\$ 14,143,237</b>
<b>Liabilities and Stockholders Equity</b>		
Current Liabilities		
Revolving line of credit	\$ 1,268,128	\$ 1,768,128
Current maturities of long-term debt	435,793	397,886
Accounts payable	603,483	1,239,827
Accrued compensation	814,579	665,083
Warranty reserve	427,764	363,277
Other accrued liabilities	37,162	68,097
<b>Total current liabilities</b>	<b>3,586,909</b>	<b>4,502,298</b>
Long-term debt, less current maturities	1,693,431	2,033,325
Deferred income taxes	145,000	145,000
<b>Total liabilities</b>	<b>5,425,340</b>	<b>6,680,623</b>
Commitments and Contingencies (Note 8)		
Stockholders Equity		
Electromed, Inc. stockholders equity:		
Common stock, \$0.01 par value; authorized: 13,000,000 shares; issued and outstanding: 8,099,885 and 6,187,885 shares, respectively	80,999	61,879
Additional paid-in capital	12,765,802	6,685,362
Retained earnings	1,689,244	797,873
Common stock subscriptions receivable for shares outstanding of 35,000 and 48,500 respectively	(55,500)	(82,500)
<b>Total stockholders equity</b>	<b>14,480,545</b>	<b>7,462,614</b>
<b>Total liabilities and stockholders equity</b>	<b>\$ 19,905,885</b>	<b>\$ 14,143,237</b>

See Notes to Condensed Consolidated Financial Statements.

Table of Contents**Electromed, Inc. and Subsidiary**  
**Condensed Consolidated Statements of Income (Unaudited)**

	For the Three Months Ended March 31,		For the Nine Months Ended March 31,	
	2011	2010	2011	2010
Net revenues	\$ 5,198,828	\$ 4,228,577	\$ 14,049,803	\$ 10,679,711
Cost of revenues	1,495,509	1,245,884	3,872,565	2,999,149
<b>Gross profit</b>	<b>3,703,319</b>	<b>2,982,693</b>	<b>10,177,238</b>	<b>7,680,562</b>
Operating expenses				
Selling, general and administrative	2,759,543	2,024,006	8,025,578	5,679,494
Research and development	272,270	194,421	689,360	445,463
<b>Total operating expenses</b>	<b>3,031,813</b>	<b>2,218,427</b>	<b>8,714,938</b>	<b>6,124,957</b>
<b>Operating income</b>	<b>671,506</b>	<b>764,266</b>	<b>1,462,300</b>	<b>1,555,605</b>
Interest expense, net of interest income of \$2,822, \$758, \$8,810, and \$4,976 respectively	38,077	58,138	150,929	205,677
<b>Net income before income taxes</b>	<b>633,429</b>	<b>706,128</b>	<b>1,311,371</b>	<b>1,349,928</b>
Income tax expense	(146,000)	(227,000)	(420,000)	(487,000)
<b>Net income</b>	<b>487,429</b>	<b>479,128</b>	<b>891,371</b>	<b>862,928</b>
Less: Net income attributable to non-controlling interest		(4,470)		(17,238)
<b>Net income attributable to Electromed, Inc.</b>	<b>\$ 487,429</b>	<b>\$ 474,658</b>	<b>891,371</b>	<b>\$ 845,690</b>
Earnings per share attributable to Electromed, Inc. common shareholders:				
Basic and Diluted	\$ 0.06	\$ 0.08	\$ 0.12	\$ 0.14
Weighted-average Electromed, Inc. common shares outstanding:				
Basic	8,099,752	6,079,522	7,722,075	6,072,256
Diluted	8,112,696	6,125,772	7,750,956	6,113,717

See Notes to Condensed Consolidated Financial Statements.

Table of Contents**Electromed, Inc. and Subsidiary  
Condensed Consolidated Statements of Cash Flows (Unaudited)**

	<b>For the Nine Months Ended March 31,</b>	
	<b>2011</b>	<b>2010</b>
<b>Cash Flows From Operating Activities</b>		
Net income	\$ 891,371	\$ 862,888
Adjustments to reconcile net income to net cash provided by (used in) operating activities:		
Depreciation	246,426	223,107
Amortization of finite-life intangible assets	83,848	34,323
Amortization of debt issuance costs	27,778	40,384
Share-based compensation expense	129,396	125,846
Deferred income taxes		(153,000)
Loss on disposal of property and equipment	15,758	3,728
Issuance of common stock for payment of services		22,500
Changes in operating assets and liabilities:		
Accounts receivable	(2,655,542)	(553,884)
Inventories	(194,190)	(74,612)
Prepaid expenses and other assets	(149,566)	(67,072)
Accounts payable and accrued liabilities	329,215	629,158
<b>Net cash provided by (used in) operating activities</b>	<b>(1,275,506)</b>	<b>1,093,366</b>
<b>Cash Flows From Investing Activities</b>		
Expenditures for property and equipment	(315,456)	(189,828)
Purchase of noncontrolling interest in Electromed Financial, LLC		(125,000)
Expenditures for finite-life intangible assets	(648,616)	(509,162)
<b>Net cash used in investing activities</b>	<b>(964,072)</b>	<b>(823,990)</b>
<b>Cash Flows From Financing Activities</b>		
Net borrowings (payments) on revolving line of credit	(500,000)	1,268,128
Proceeds from long-term debt		2,520,000
Principal payments on long-term debt including capital lease obligations	(327,113)	(3,543,933)
Payments of deferred financing fees	(6,717)	(75,780)
Proceeds from warrant exercises	24,000	73,332
Proceeds from sales of 1.9 million shares of common stock, net of offering costs of \$1,236,287	6,363,713	
Expenditures for IPO costs		(328,768)
Repurchase of common stock		(18,418)
Proceeds from subscription notes receivable	27,000	9,000
<b>Net cash provided by (used in) financing activities</b>	<b>5,580,883</b>	<b>(96,438)</b>
<b>Net increase in cash and cash equivalents</b>	<b>3,341,305</b>	<b>172,938</b>
Cash and cash equivalents		
Beginning of period	610,727	361,916
End of period	\$ 3,952,032	\$ 534,854

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

**Electromed, Inc. and Subsidiary**  
**Notes to Condensed Consolidated Financial Statements**  
**(Unaudited)**

**Note 1. Interim Financial Reporting**

**Basis of presentation:** Electromed, Inc. (the Company) develops, manufactures and markets innovative airway clearance products which apply High Frequency Chest Wall Oscillation (HFCWO) therapy in pulmonary care for patients of all ages. The Company markets its products in the United States to the home health care and institutional markets for use by patients in personal residences, hospitals and clinics. The Company also sells internationally both directly and through distributors. Since its inception, the Company has operated in a single industry segment: developing, manufacturing and marketing medical equipment.

The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles for interim financial statements and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of management, the accompanying unaudited consolidated financial statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of its financial position and results of operations as required by Regulation S-X, Rule 10-01. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. generally accepted accounting principles for annual reports. This interim report should be read in conjunction with the consolidated financial statements included in the Company's annual report on Form 10-K for the year ended June 30, 2010.

The Company has evaluated subsequent events and transactions for potential recognition or disclosure in the financial statements through the day the financial statements are issued.

**Principles of consolidation:** The accompanying condensed consolidated financial statements include the accounts of Electromed, Inc. and its subsidiary, Electromed Financial, LLC. Electromed Financial, LLC was established by the Company to assist in raising capital from outside investors. The Company owned 95 percent of Electromed Financial, LLC through March 2, 2010, at which time the Company acquired the remaining five percent of Electromed Financial, LLC from a director and executive officer of the Company for \$125,000. Income related to the non-controlling interest in the subsidiary is reflected as non-controlling interest on the consolidated financial statements. All significant intercompany accounts and transactions have been eliminated in consolidation.

**Use of estimates:** Management uses estimates and assumptions in preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its consolidated financial statements include: revenue recognition and the estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence and warranty liability.

**Net income per common share:** Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period. The diluted net income per common share calculation assumes that all stock warrants were exercised and converted into common stock at the beginning of the period, unless their effect would be anti-dilutive. For the nine months ended March 31, 2011 common stock equivalents of 567,800, were excluded from the calculation of diluted earnings per share as their impact was antidilutive.

**Reclassifications:** Certain items in the fiscal 2010 financial statements have been reclassified to be consistent with the classifications adopted for fiscal 2011. The fiscal 2010 reclassifications had no impact on previously reported net income or stockholders' equity.



Table of Contents**Note 2. Inventories**

The components of inventory were approximately as follows:

	<b>March 31, 2011</b>	<b>June 30, 2010</b>
Parts inventory	\$ 961,000	\$ 765,000
Work in process	232,000	56,000
Finished goods	502,000	680,000
Less: Reserve for obsolescence	(30,000)	(30,000)
Total	\$ 1,665,000	\$ 1,471,000

**Note 3. Finite-Life Intangible Assets**

The carrying value of patents and trademarks includes the original cost of obtaining the patents, periodic renewal fees, and other costs associated with maintaining and defending patent and trademark rights. Patents and trademarks are amortized over their estimated useful lives, generally 15 and 12 years, respectively. Accumulated amortization was \$198,000 and \$114,000 at March 31, 2011 and June 30, 2010, respectively.

The activity and balances of finite-life intangible assets were approximately as follows:

	<b>Nine Months Ended March 31, 2011</b>	<b>Year Ended June 30, 2010</b>
Balance, beginning	\$ 1,056,000	\$ 229,000
Additions	283,000	880,000
Amortization expense	(84,000)	(53,000)
Balance, ending	\$ 1,255,000	\$ 1,056,000

Additions consisted primarily of legal defense costs associated with a trademark infringement lawsuit which the Company successfully defended as discussed further in Note 8.

Table of Contents**Note 4. Warranty Liability**

The Company provides a lifetime warranty on its products to the prescribed patient for sales within the United States and Canada, a five-year warranty on its products to the prescribed patient for sales within Greece, and a three-year warranty for all institutional sales and sales to individuals outside the United States and Canada. The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is sold. The Company periodically assesses the adequacy of its recorded liability and adjusts the amounts as necessary. Changes in the Company's warranty liability were approximately as follows:

	<b>Nine Months Ended March 31, 2011</b>	<b>Year Ended June 30, 2010</b>
Beginning warranty reserve	\$ 363,000	\$ 292,000
Accrual for products sold	220,000	146,000
Expenditures and costs incurred for warranty claims	(155,000)	(75,000)
Ending warranty reserve	\$ 428,000	\$ 363,000

**Note 5. Income Taxes**

On a quarterly basis, the Company estimates what its effective tax rate will be for the full fiscal year and records a quarterly income tax provision based on the anticipated rate. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The effective tax rate for the nine months ended March 31, 2011 and March 31, 2010 was 32.0% and 36.1% respectively.

**Note 6. Financing Arrangements**

The Company renewed its \$3,500,000 revolving line of credit on November 30, 2010. The line of credit expires on November 30, 2011, if not renewed. Advances are due at the expiration date and are secured by substantially all the Company assets. The amount available for borrowing is limited to 60 percent of eligible accounts receivable less the outstanding balance of the Company's 4.28% term note due December 2012. Interest on advances accrues at LIBOR plus 2.75 percent (3.06% at March 31, 2011) and is payable monthly. As of March 31, 2011, there was approximately \$1,268,000 outstanding on the line of credit and had unused availability of \$2,232,000. The Company is required to pay a fee of 0.125% per annum on unused portions of the revolving line of credit.

**Note 7. Common Stock**

**Sales of common stock:** On August 13, 2010 the Company completed an initial public stock offering (IPO) of 1,700,000 shares of common stock at an offering price of \$4.00 per share. In addition on September 28, 2010, the underwriter in the IPO acquired an additional 200,000 shares at \$4.00 per share pursuant to exercise of a portion of its over-allotment option. After deducting the payment of underwriter discounts, commissions and offering costs, the net proceeds from the sale of shares in the IPO was approximately \$5,946,000.

At the annual meeting of shareholders held on November 5, 2010, the shareholders of the Company voted to amend the Company's Articles of Incorporation to increase the number of authorized shares of capital stock from 10,000,000 to 15,000,000, consisting of 13,000,000 shares of common stock par value \$0.01 per share, and 2,000,000 shares of undesignated stock.

Table of Contents

**Note 8. Commitments and Contingencies**

**Litigation:** Subsidiaries of Hill-Rom Holdings, Inc., (collectively, Hill-Rom ) brought an action on August 21, 2009, against the Company alleging that the Company's use of the term SmartVest infringes on its alleged trademark The Vest . For the nine months ended March 31, 2011 and the year ended June 30, 2010, the Company incurred and capitalized costs of approximately \$283,000 and \$880,000 respectively in defending this trademark. On September 30, 2010, the companies reached a settlement to the lawsuit. The terms of the Settlement Agreement are confidential, but will not prohibit the Company's continued use of its SmartVest® marks.

In addition to the trademark matter discussed above, the Company is occasionally involved in claims and disputes arising in the ordinary course of business. The Company insures its business risks where possible to mitigate the financial impact of individual claims, and establishes reserves for an estimate of any probable cost of settlement or other disposition.

**Note 9. Related Parties**

The Company uses a related-party service provider, a director and minority shareholder of which was the original inventor of the Company's product, to perform certain outsourced research and development functions. The Company's chief executive officer is also president, chief executive officer and chairman of the board of directors of the service provider and owns approximately 11% of that entity's outstanding common stock. In addition, two members of the Company's board of directors are directors and minority shareholders of the service provider. The Company has an agreement with the service provider which provides that the service provider will perform 80 hours per week of research and development work in exchange for a monthly fee, in the amount of \$30,000. The agreement, which remains in effect for successive six-month terms until terminated by either party, was automatically renewed at December 31, 2010. For the nine months ended March 31, 2011 and 2010, expenses for these services totaled approximately \$276,000 and \$175,000 respectively, and such expenses are included in research and development expense in the income statement.

Table of Contents

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

*Some of the statements in this report may contain forward-looking statements that reflect our current view on future events, future business, industry and other conditions, our future performance, and our plans and expectations for future operations and actions. In some cases, you can identify forward-looking statements by the following words: anticipate, believe, continue, could, estimate, expect, intend, may, ongoing, plan, potential, predict, project, should, will, would, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Our forward-looking statements in this report primarily relate to the following: our ability to receive reimbursement for our products; our ability to gain market share; impact of our business strategy on revenues and earnings, including the expected contributions of new members of our sales staff; expected expenditures for research and development; anticipated expenses related to our intellectual property; future innovations in our product offerings; and our beliefs regarding the sufficiency of working capital and our ability to renew or obtain financing. These statements involve known and unknown risks, uncertainties and other factors that may cause our results or our industry's actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Forward-looking statements are only predictions and are not guarantees of performance. These statements are based on our management's beliefs and assumptions, which in turn are based on currently available information.*

*You should read this report thoroughly with the understanding that our actual results may differ materially from those set forth in the forward-looking statements for many reasons, including events beyond our control and assumptions that prove to be inaccurate or unfounded. Our actual results or actions could and likely will differ materially from those anticipated in the forward-looking statements for many reasons, including the reasons described in this report. These factors include, but are not limited to: the competitive nature of our market; the risks associated with expansion into international markets; changes to Medicare, Medicaid, or private insurance reimbursement policies; changes to health care laws; changes affecting the medical device industry; our need to maintain regulatory compliance and to gain future regulatory approvals and clearances; our ability to recruit, train and retain an effective sales force, reimbursement staff, and patient services staff; our ability to protect our intellectual property; the effect of litigation, including legal expenses, that may arise with respect to our intellectual property in the ordinary course of business or otherwise; the impact of tight credit markets on our ability to continue to obtain financing on reasonable terms; and general economic and business conditions.*

**Overview**

Electromed, Inc. ( we, us, our, the Company, or Electromed ) was incorporated in 1992. We are engaged in the business of providing innovative airway clearance products applying High Frequency Chest Wall Oscillation ( HFCWO ) technologies in pulmonary care for patients of all ages.

**We manufacture, market and sell products that provide HFCWO, including the Electromed, Inc. SmartVest® Airway Clearance System ( SmartVest System ) and related products, to patients with compromised pulmonary function. The products are sold for both the home health care market and the institutional market for use by patients in hospitals, which are referred to as institutional sales. For approximately ten years, we have marketed the SmartVest System and its predecessor products to patients suffering from cystic fibrosis, chronic obstructive pulmonary disease ( COPD ), bronchiectasis and related conditions which can result in repeated episodes of pneumonia. Additionally, we offer such products, upon physician prescription to a patient population that includes post-surgical and intensive care patients at risk of developing pneumonia, patients with end-stage neuromuscular disease, and ventilator-dependent patients. Our goal is to be a consistent innovator in providing HFCWO to patients with compromised pulmonary function.**

Table of Contents**Critical Accounting Policies and Estimates**

Our significant accounting policies and estimates are disclosed in Part II, Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations, and Note 1 to our Audited Consolidated Financial Statements, included in Part II, Item 8, of our Annual Report on Form 10-K for the fiscal year ended June 30, 2010. The critical accounting policies used in the preparation of the financial statements as of March 31, 2011 have remained unchanged from June 30, 2010.

Some of our accounting policies require us to exercise significant judgment in selecting the appropriate assumptions for calculating financial statements. Such judgments are subject to an inherent degree of uncertainty. These judgments are based upon our historical experience, known trends in our industry, terms of existing contracts and other information from outside sources, as appropriate. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its consolidated financial statements include: revenue recognition and the estimation of selling price adjustments, allowance for doubtful accounts, inventory obsolescence and warranty liability.

**Results of Operations***Three Months Ended March 31, 2011 Compared to Three Months Ended March 31, 2010**Revenues*

Revenue results for the three month periods are summarized in the table below (dollar amounts in thousands).

	Three Months Ended March 31,		Increase (Decrease)	
	2011	2010		
<b>Total Revenue</b>	\$ 5,199	\$ 4,229	\$ 970	22.9%
<b>Home Care Revenue</b>	\$ 4,689	\$ 3,726	\$ 963	25.8%
<b>International Revenue</b>	\$ 143	\$ 267	\$ (124)	(46.4)%
<b>Government/Institutional Revenue</b>	\$ 367	\$ 236	\$ 131	55.5%

*Home Care Revenue.* Home care revenue was approximately \$4,689,000 for the three months ended March 31, 2011, representing an increase of approximately \$963,000, or 25.8%, compared to the same period in 2010. This resulted from a 24.1% increase in referrals, from 576 in the three months ended March 31, 2010, to 715 in the same period in the current year. The increase in revenues and the increase in referrals reflect an increase in the existing sales staff from 15 full time equivalents (FTE's) in the three months ended March 31, 2010, to 23 in the same period in the current year. A larger sales force has allowed us to expand our presence into new territories and to increase our penetration in territories in which we have previously sold the SmartVest System.

*International Revenue.* International revenue was approximately \$143,000 for the three months ended March 31, 2011, representing a decrease of approximately \$124,000, or 46.4%, compared to the same period in 2010. This resulted primarily from a decrease in sales to Europe from approximately \$151,000 in the three months ended March 31, 2010 to approximately \$70,000 in the comparable period in 2011, and a decrease in sales in Asia from approximately \$101,000 in the three months ended March 31, 2010 to approximately \$68,000 in the comparable period in 2011. Sales to other regions decreased by approximately \$10,000 during this period from 2010 to 2011.

Table of Contents

*Government/Institutional Revenue.* Government/institutional revenue was approximately \$367,000 for the three months ended March 31, 2011, representing an increase of approximately \$131,000, or 55.5%, compared to approximately \$236,000 during the same period in 2010. Government revenues rose to approximately \$90,000 in the third quarter of 2011 compared to approximately \$65,000 during the same period the prior year. Sales to distributors, group purchasing organization ( GPO ) members, and other institutions rose to approximately \$277,000 in the third quarter of 2011 compared to approximately \$171,000 during the same period the prior year as the efforts of our larger sales force continued to produce higher sales.

***Gross Profit***

Gross profit increased to approximately \$3,703,000, or 71.2% of net revenues, for the three months ended March 31, 2011, from approximately \$2,983,000, or 70.5% of net revenues in the same period in 2010. The increase in gross profit dollars resulted primarily from an increase in sales volume.

***Operating expenses***

*Selling, general and administrative expenses.* Selling, general and administrative expenses were approximately \$2,759,000 for the three months ended March 31, 2011, representing an increase of approximately \$735,000, or 36.3%, compared to selling, general and administrative expenses of approximately \$2,024,000 for the same period the prior year. Payroll and compensation-related expenses were approximately \$1,376,000 for the three months ended March 31, 2011, representing an increase of approximately \$351,000, or 34.2%, compared to approximately \$1,025,000 in the same period the prior year. This increase primarily resulted from a 46.2% increase in total employees from an average of 39 SG&A FTE employees in 2010 compared to an average of 57 SG&A FTE employees in 2011.

Health insurance costs for full-time employees were approximately \$92,000 for the three months ended March 31, 2011, representing a decrease of approximately \$38,000, or 29.3%, from approximately \$130,000 in 2010. This decrease resulted primarily from management adjusting the employee participation amount of the health insurance cost. Travel, meals and entertainment, and trade show expenses were approximately \$404,000 in the three months ended March 31, 2011, representing an increase of approximately \$167,000, or 70.5%, compared to approximately \$237,000 the same period in the prior year. This increase is primarily due to the 53.3% increase in the size of the sales force and the overall number of trade shows in which Electromed participated.

Advertising and marketing expenses for the three months ended March 31, 2011 were approximately \$219,000, an increase of approximately \$74,000, or 51.0% compared to approximately \$145,000 in the same period the prior year. These increased expenditures related to providing marketing support to a larger sales team.

Patient training expenses for the three months ended March 31, 2011 were approximately \$125,000, an increase of approximately \$27,000, or 27.6% compared to approximately \$98,000 in the same period the prior year. These increases reflected the increased volume of home care patient referrals for the three months ended March 31, 2011 compared to the same period the prior year.

Professional fees for the three months ended March 31, 2011 were approximately \$170,000, an increase of approximately \$120,000 compared to approximately \$50,000 in the same period the prior year. This was primarily the result of services related to greater reporting requirements, expenses related to security and backup, consulting expenses, and expenses for printing and shareowner services related to the transition to a public company.

Table of Contents

*Research and development expenses.* Research and development expenses were approximately \$272,000 for the three months ended March 31, 2011, representing an increase of approximately \$78,000, or 40.2%, compared to approximately \$194,000 in the same period the prior year. The increase is related to efforts directed toward system design and performance and possible product additions to the SmartVest® line. Research and development costs for the three months ended March 31, 2011 were 5.2% of revenue, compared to 4.6% of revenue in the same period the prior year. Management plans for research and development expenses to be approximately 5% or greater of revenue in the future.

*Interest expense*

Interest expense was approximately \$41,000 for the three months ended March 31, 2011 representing a decrease of approximately \$18,000, or 30.5%, compared to approximately \$59,000 for the same period the prior year. The decrease resulted from a combination of a decrease in average debt outstanding due to payments on term loans and a decrease in the amount of loan charges amortized relating to our outstanding credit agreements.

*Income tax expense*

Income tax expense is estimated at approximately \$146,000 for the three months ended March 31, 2011 compared to \$227,000 in the same period the prior year. The effective tax rates for the three months ended March 31, 2011 and March 31, 2010 were 23.0% and 32.1% respectively. The lower effective tax rate for the three months ended March 31, 2011 was due to discrete items recorded in the third quarter related to higher than originally estimated tax credits and differences from the filing of the 2010 income tax return over the amount originally estimated.

*Net income*

Net income for the three months ended March 31, 2011 was approximately \$487,000, or 9.4% of revenues at the time of the writing of this report, compared to approximately \$475,000, or 11.2% of revenues, for the same period the prior year. The decrease in net income as a percentage of revenues primarily resulted from increases in expenses designed to develop, support and maintain a higher sales level. Management continues to believe the increases in sales force, support and production personnel coupled with an aggressive expansion of marketing and research and development efforts is providing the foundation for a successful increase in market share.

Table of Contents*Nine Months Ended March 31, 2011 Compared to Nine Months Ended March 31, 2010***Revenues**

Revenue results for the nine month periods are summarized in the table below (dollar amounts in thousands).

	Nine Months Ended March 31,		Increase (Decrease)	
	2011	2010		
<b>Total Revenue</b>	\$ 14,050	\$ 10,680	\$ 3,370	31.6%
<b>Home Care Revenue</b>	\$ 12,738	\$ 9,708	\$ 3,030	31.2%
<b>International Revenue</b>	\$ 501	\$ 542	\$ (41)	(7.6)%
<b>Government/Institutional Revenue</b>	\$ 811	\$ 430	\$ 381	88.6%

*Home Care Revenue.* Home care revenue was approximately \$12,738,000 for the nine months ended March 31, 2011, representing an increase of approximately \$3,030,000, or 31.2%, compared to approximately \$9,708,000 for the same period in 2010. This resulted from a 28% increase in referrals, advancing from 1,541 in the nine months ended March 31, 2010 to 1,972 in the same period in 2011. The increase in revenues and the increase in referrals resulted primarily from a 50% increase in our existing sales staff, from 14 FTE s in the nine months ended March 31, 2010, to 21 FTE s in the comparable period in 2010. Although the percentage increase in sales has not equaled the increase in our sales force, management believes the new members of our sales staff will contribute more as their experience and customer contacts grow.

*International Revenue.* International revenue was approximately \$501,000 for the nine months ended March 31, 2011, representing a decrease of approximately \$41,000, or 7.6%, compared to approximately \$542,000 the same period the prior year. This resulted from a decrease in sales to Europe from approximately \$345,000 in the nine months ended March 31, 2010 to approximately \$252,000 in the comparable period in 2011, and an increase in sales in Asia from approximately \$125,000 in the nine months ended March 31, 2010 to approximately \$197,000 in the comparable period in 2011. Sales to other regions decreased from approximately \$72,000 in the nine months ended March 31, 2010, to approximately \$52,000 in the comparable period in 2011.

*Government/Institutional Revenue.* Government/institutional revenue was approximately \$811,000 for the nine months ended March 31, 2011, representing an increase of approximately \$381,000, or 88.6%, compared to approximately \$430,000 the same period in 2010. Government revenues rose to approximately \$187,000 in the nine months ended March 31, 2011, compared to approximately \$100,000 during the same period the prior year, and sales to distributors, GPO members, and other institutions rose to approximately \$624,000 in the third quarter of 2011 compared to approximately \$330,000 during the same period the prior year as the efforts of our larger sales force continued to produce higher sales.



Table of Contents

***Gross Profit***

Gross profit increased to \$10,177,000, or 72.4% of net revenues, for the nine months ended March 31, 2011, from approximately \$7,681,000 million, or 71.9% of net revenues in the same period in 2010. The increase in gross profit dollars resulted primarily from the increase in sales volume.

***Operating expenses***

*Selling, general and administrative expenses.* Selling, general and administrative expenses were approximately \$8,026,000 for the nine months ended March 31, 2011, representing an increase of approximately \$2,347,000, or 41.3%, compared to selling, general and administrative expenses of approximately \$5,679,000 for the same period the prior year. Payroll and compensation-related expenses were approximately \$3,727,000 for the nine months ended March 31, 2011, representing an increase of approximately \$1,050,000, or 39.2%, compared to payroll and compensation-related expenses of approximately \$2,677,000 in the same period the prior year. This increase primarily resulted from a 47.2% increase in employees from an average of 36 FTE SG&A employees for the nine months ended March 31, 2010 compared to an average of 53 FTE SG&A employees for the same period the current year.

Health insurance costs for full-time employees were approximately \$422,000 for the nine months ended March 31, 2011, representing an increase of approximately \$77,000, or 22.3%, from approximately \$345,000 in 2010. This increase resulted primarily from an increase in the number of participants in the health insurance plan as the number of qualifying employees increased offset by management adjusting the employee participation amount of the health insurance cost in the third quarter. Travel, trade show, and meals and entertainment expenses were approximately \$1,189,000 in the nine months ended March 31, 2011, representing an increase of approximately \$413,000, or 53.2%, compared to approximately \$776,000 the same period in the prior year. This increase was primarily due to the 50% increase in the size of the sales force along with increased travel costs from management in connection with training new staff.

Advertising and marketing expenses for the nine months ended March 31, 2011 were approximately \$705,000, an increase of approximately \$314,000, or 80.3% compared to approximately \$391,000 in the same period the prior year. These increased expenditures related to providing greater marketing support to a larger sales team. Patient training expenses for the nine months ended March 31, 2011 were approximately \$343,000, an increase of approximately \$88,000, or 34.5% compared to approximately \$255,000 in the same period the prior year. These increases reflected the increased volume of home care patient referrals for the nine months ended March 31, 2011 compared to the same period the prior year.

*Research and development expenses.* Research and development expenses were approximately \$689,000 for the nine months ended March 31, 2011, representing an increase of approximately \$244,000, or 54.8%, compared to approximately \$445,000 in the same period the prior year. The increase is related to various research projects related to system design and performance, enhancements to therapy garments and possible product additions to the SmartVest line. Research and development costs for the nine months ended March 31, 2011 were 4.9% of revenue, compared to 4.2% of revenue for the same period the prior year. Management plans for research and development expense to be approximately 5% or greater of revenue in the future.

***Interest expense***

Interest expense was approximately \$160,000 for the nine months ended March 31, 2011 representing a decrease of approximately \$51,000, or 24.2%, compared to approximately \$211,000 for the same period the prior year. The decrease resulted from a combination of a decrease in average debt outstanding due to payments on term loans, lower average interest rates on outstanding debt, and a decrease in the amount of loan charges amortized relating to our outstanding credit agreements.

Table of Contents

***Income tax expense***

Income tax expense was estimated at approximately \$420,000 for the nine months ended March 31, 2011, compared to \$487,000 in the same period the prior year. The effective tax rates for the nine months ended March 31, 2011 and March 31, 2010 were 32.0% and 36.1% respectively. The lower effective tax rate for the nine months ended March 31, 2011 was due to discrete items recorded in the third quarter related to higher than originally estimated tax credits and differences from the filing of the 2010 income tax return over the amount originally estimated.

***Net income***

Net income for the nine months ended March 31, 2011, was approximately \$891,000, or 6.3% of revenues, compared to approximately \$846,000, or 7.9% of revenues, for the same period the prior year. The decrease in net income as a percentage of revenues primarily resulted from increases in expenses designed to develop, support and maintain a higher sales level. Management continues to believe the increases in sales force, support and production personnel coupled with an aggressive expansion of marketing and research and development efforts is providing the foundation for a successful increase in market share.

**Liquidity and Capital Resources**

***Cash Flows and Sources of Liquidity***

***Cash Flows from Operating Activities***

For the nine months ended March 31, 2011, net cash used by operating activities was approximately \$1,276,000. Cash flows used by operations consisted of approximately \$891,000 in net income, adjusted for non-cash expenses of approximately \$504,000, offset by increases in accounts receivable, inventory, and prepaid expenses of \$2,656,000, \$194,000, and \$150,000 respectively. In addition, trade payables and other accrued liabilities increased approximately \$329,000.

For the nine months ended March 31, 2010, net cash provided by operating activities was approximately \$1,093,000. Cash flows provided by operations were primarily a result of net income adjusted for non-cash expenses of approximately \$1,160,000, offset by increases in accounts receivable, inventories and prepaid expenses of approximately \$554,000, \$75,000 and \$67,000 respectively. In addition, trade payables and other accrued liabilities increased by approximately \$629,000.

Management believes that the net cash used by operating activities during the nine months ended March 31, 2011 was attributable, in part, to the significant investment in sales and marketing designed to increase sales, combined with the normal lag in collecting accounts receivable from third-party payors, as demonstrated by the increase in accounts receivable of approximately \$2,656,000 for the nine months ended March 31, 2011, as compared to approximately \$554,000 for the nine months ended March 31, 2010.

***Cash Flows from Investing Activities***

For the nine months ended March 31, 2011 cash used in investing activities was approximately \$964,000. During this period the Company paid approximately \$649,000 in costs related to defending the SmartVest® trademark and approximately \$315,000 for purchases of property and equipment.

For the nine months ended March 31, 2010, cash used for investing activities was approximately \$824,000. During this period the Company paid approximately \$509,000 in costs related to defending the SmartVest® trademark, \$125,000 for the purchase of the non-controlling interest in Electromed Financial, LLC, and approximately \$190,000 for the purchase of equipment.

Table of Contents

*Cash Flows from Financing Activities*

For the nine months ended March 31, 2011, cash provided by financing activities was approximately \$5,581,000, consisting of approximately \$6,388,000 net proceeds during the nine month period from the issuance of common stock in our initial public offering (IPO) and \$27,000 in proceeds from subscription notes receivable. This was offset by net payments on a revolving credit line of \$500,000, principal payments on long-term debt of approximately \$327,000 and payment of deferred financing fees of approximately \$7,000.

For the nine months ended March 31, 2010, cash used by financing activities was approximately \$96,000, consisting of approximately \$1,268,000 net borrowings on a revolving line of credit along with proceeds from long-term debt of approximately \$2,520,000 and approximately \$82,000 from the sale of common stock and receipts on subscription notes receivable, offset by payments on long-term debt of approximately \$3,544,000, expenditures for IPO costs of approximately \$329,000, payment of deferred financing fees of approximately \$76,000, and payment of non-controlling interest distributions of approximately \$18,000 in Electromed Financial, LLC.

*Adequacy of Capital Resources*

We believe, based on our current operational performance, our available borrowings under our existing credit facility and available cash from the successful completion of our IPO are sufficient to meet our liquidity needs for, at a minimum, the next twelve months. We may need to incur additional indebtedness if we have an unforeseen need for additional capital equipment or if our operating performance does not generate adequate cash flow.

Our primary capital requirements relate to adding employees in our Reimbursement, Patient Services and Administrative Departments; adding members to our sales force; continuing research and development efforts; and for general corporate purposes, including to finance equipment purchases and other capital expenditures in the ordinary course of business and to satisfy working capital needs.

For the first nine months of fiscal 2011 and 2010, respectively, we spent approximately \$315,000 and \$190,000 on property and equipment. We currently expect to finance equipment purchases with borrowings under the credit facility and with available cash. In addition, we have incurred and capitalized approximately a total of \$1,163,000 of legal defense costs associated with a trademark lawsuit, which was settled pursuant to a confidential settlement agreement on September 30, 2010. Accordingly, we anticipate future costs associated with intellectual property to be at significantly lower levels.

We currently have a credit facility with U.S. Bank, National Association ( U.S. Bank ) that provides for a \$3,500,000 revolving line of credit and \$2,520,000 in term debt. A \$1,520,000 Term Loan bears interest at 5.79% ( Term Loan A ). The remaining \$1,000,000 term loan bears interest at 4.28% ( Term Loan B ). Interest on the operating line of credit accrues at LIBOR plus 2.75% (3.06% at March 31, 2011) and is payable monthly. The amount eligible for borrowing on the line of credit is limited to 60% of eligible accounts receivable less the outstanding balance on our Term Loan B. The line of credit is scheduled to expire on November 30, 2011, if not renewed. Term Loan A requires monthly payments of principal and interest of approximately \$10,700 and has a maturity date of December 9, 2014. Term Loan B requires monthly payments of principal and interest of approximately \$29,600 and has a maturity date of December 9, 2012. As of March 31, 2011, we had approximately \$1,268,000 outstanding on the operating line of credit and approximately \$2,034,000 outstanding on the term loan debt for a total outstanding under the U.S. Bank credit facility of \$3,302,000. As of March 31, 2011, we had net unused availability of \$2,232,000 under the line of credit. We are required to pay a fee of 0.125% per annum on unused portions of the revolving line of credit.

## Table of Contents

The agreement governing the credit facility contains certain covenants that restrict our ability to, among other things, pay cash dividends, incur indebtedness or liens, change Chief Executive Officer or Chief Financial Officer, merge or consolidate with any person, or sell, lease, assign, transfer or otherwise dispose of any assets other than in the ordinary course of business. The agreement also contains financial covenants that require maintenance of certain fixed charge and cash flow coverage ratios. Our obligations under the U.S. Bank credit facility are secured by substantially all of our assets and are guaranteed by our wholly owned subsidiary, Electromed Financial, LLC.

On August 13, 2010, we completed the sale of 1,700,000 shares of common stock, par value \$0.01 per share, in an IPO, at an offering price of \$4.00 per share. On September 28, 2010, Felt and Company, Inc., the underwriter of the IPO, acquired 200,000 shares of our common stock at a price of \$4.00 per share, pursuant to exercise of its over-allotment option. Gross proceeds from the issuance of common stock in connection with the IPO, including the over-allotment option, were approximately \$7,600,000. After deducting the payment of underwriters discounts and commissions and offering expenses, our net proceeds from the sale of shares in the IPO, including the over-allotment option, were approximately \$5,946,000.

### **Certain Information Concerning Off-Balance Sheet Arrangements**

We have no off-balance sheet arrangements.

### **Item 3. Quantitative and Qualitative Disclosure About Market Risk**

Not applicable to smaller reporting companies.

### **Item 4. Controls and Procedures**

#### **Evaluation of Disclosure Controls and Procedures**

Our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) or Rule 15d-15(e), as of the end of the period subject to this Report. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our periodic and current reports that are filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the periods specified by the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer as appropriate to allow timely decisions regarding required disclosures.

#### **Changes to Internal Control Over Financial Reporting**

There were no changes in our internal control over financial reporting that occurred during the first nine months of fiscal 2011 that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting.

## **PART II. OTHER INFORMATION**

### **Item 1. Legal Proceedings**

As previously disclosed in Part II, Item I of our Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2010, we reached a definitive settlement agreement on September 30, 2010, with respect to our litigation with Hill-Rom Services, Inc., ARI, Hill-Rom Company, Inc., and Hill-Rom Services Pte. Ltd. (collectively, Hill-Rom). The terms of the settlement are confidential. We have no plans to change our use of the SmartVest® marks.

## Table of Contents

In addition to the foregoing, we may be party to legal actions, proceedings, or claims in the ordinary course of business. Corresponding costs are accrued when it is more likely than not that we will incur a loss and the amount can be precisely or reasonably estimated. We are not aware of any undisclosed actual or threatened litigation that would have a material adverse effect on its financial condition or results of operations.

### **Item 1A. Risk Factors**

Not applicable to smaller reporting companies.

### **Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

#### **Unregistered Sales of Equity Securities**

On January 1, 2011, we issued 12,000 shares of common stock to an employee pursuant to a warrant exercise for cash consideration of \$24,000. The transaction did not involve an underwriter. We believe the transaction was exempt from the registration requirements of the Securities Act of 1933, as amended, by virtue of Section 4(2) thereof, based on the limited number of offerees and the identity of the offeree as an executive officer of the Company, and Section 3(a)(9) thereof and Rule 701 promulgated thereunder, because the sale was made pursuant to a written compensatory benefit contract, and the offer of the securities commenced prior to the time the Company became subject to Exchange Act reporting obligations.

#### **Use of Proceeds**

We completed our IPO of shares of common stock, \$0.01 par value during the fiscal quarter ended September 30, 2010. The effective date of the registration statement relating to the IPO, filed on Form S-1 under the Securities Act of 1933 (File No. 333-166470), was August 12, 2010. A total of 1,700,000 shares of common stock were registered and sold in the IPO. In addition, we granted Feltl and Company, Inc. ( Feltl ), the underwriter of the IPO, warrants to purchase up to 170,000 additional shares of our common stock at a price of \$4.80 per share and an over-allotment option to purchase 255,000 shares at \$4.00 per share, less an underwriting discount of \$0.30 per share. On September 28, 2010, Feltl exercised its over-allotment option to acquire 200,000 additional shares of common stock. As a result of this exercise, Feltl also received warrants to purchase up to 20,000 additional shares of our common stock.

The aggregate offering price of the securities sold in the IPO, including the shares sold to Feltl upon exercise of its over-allotment option, was equal to \$7,600,000. The aggregate underwriting discount for shares sold in the offering and pursuant to the over-allotment option was equal to \$570,000, none of which was or will be paid to our affiliates. We incurred approximately \$1,084,000 of offering costs in connection with the IPO. We received net proceeds from the IPO of approximately \$5,946,000. We have used \$500,000 to reduce the amount of existing indebtedness under our credit facility with U.S. Bank, National Association. We have used and intend to use the remainder of the proceeds from the offering, if necessary, to add employees to our Reimbursement, Patient Services and Administrative Departments; add members to our sales force and further develop its focus on institutional sales; continue its research and development efforts; and for general corporate purposes, including to finance equipment purchases and other capital expenditures in the ordinary course of business and to satisfy working capital needs.

### **Item 3. Defaults Upon Senior Securities**

None.

Table of Contents

**Item 4. (Removed and Reserved)**

**Item 5. Other Information**

None.

**Item 6. Exhibits**

See attached exhibit index.

Table of Contents

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 13, 2011

ELECTROMED, INC.

/s/ Robert D. Hansen  
Robert D. Hansen, Chief Executive Officer  
(Principal Executive Officer)

/s/ Terry M. Belford  
Terry M. Belford, Chief Financial Officer  
(Principal Financial Officer)

- 21 -

---

Table of Contents

**EXHIBIT INDEX  
ELECTROMED, INC.  
FORM 10-Q**

<b>Exhibit Number</b>	<b>Description</b>
10.1	Summary of Director Compensation, as of February 11, 2011
31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

- 22 -

---